Challenges in the Management of VIPoma Patients Abstract #244

Introduction: VIPomas are a rare neuroendocrine tumor (NET). 90% are pancreatic. 40-70% are metastatic at presentation. The VIPoma syndrome is characterized by secretory diarrhoea, hypokalaemia and achlorhydria.
Aim(s): To review the complexities of management and outcome in a case series of six VIPoma patients with long-term follow-up.
Materials and methods: A retrospective study of six VIPoma patients (two male, four female; age 33-72 years at presentation) was performed. Diagnosis was based on the presence of compatible symptoms, plasma VIP levels, imaging and histopathology. Clinical management and course was reviewed. Follow-up was complete in all patients (range 72 – 168 months, median 84 months).
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Fatima El-Khouly

To read results and conclusion, please login ...

Further abstracts you may be interested in

#251 Ki-67 is a Better Prognostic Marker than Mitotic Count in Neuroendocrine Tumors
Introduction: The recent classification system proposed by ENETS assigns grade by Ki-67 index +/- mitotic count. It has been adopted into routine practice but there is limited data on the relationship between them.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#1106 Salvage Treatment with Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Advanced VIPomas and Severe Verner-Morrison Syndrome
Introduction: PRRT is an effective treatment option for advanced Neuroendocrine Tumours
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT VIP
#3042 The Use of Total Parenteral Nutrition in a Series of Patients with Neuroendocrine Tumours in United Kingdom and the Netherlands
Introduction: There are controversies about the use of total parental nutrition (TPN) in patients with cancer. Currently data regarding TPN use in patients with neuroendocrine tumours (NETs) are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Dominique Clement
#3071 Hormonal Ectopic Secretion Syndromes Associated to Neuroendocine Neoplasia
Introduction: Neuroendocrine neoplasias (NEN) are able to produce and secrete bioactive peptides and cause distinct syndromes related to their biological effects. The outcome will depend on the oncological disease as well as the hormonal syndrome
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD Julieta Tkatch
#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan